Download PDF
Int J Angiol 2018; 27(03): 121-131
DOI: 10.1055/s-0036-1572523
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Risk and Benefits of Statins in Glucose Control Management of Type II Diabetes

Anthony Paulo Sunjaya
1   Faculty of Medicine, Tarumanagara University, Jakarta, Indonesia
,
Angela Felicia Sunjaya
1   Faculty of Medicine, Tarumanagara University, Jakarta, Indonesia
,
Samuel Halim
2   Department of Internal Medicine, Faculty of Medicine, Tarumanagara University, Jakarta, Indonesia
,
Frans Ferdinal
3   Department of Biochemistry, Faculty of Medicine, Tarumanagara University, Jakarta, Indonesia
› Author Affiliations
Further Information

Publication History

Publication Date:
18 February 2016 (online)

    Permissions and Reprints

Abstract

Worldwide statins are considered to be the first-line pharmacological treatment for dyslipidemia and reducing the risk of coronary heart disease. However, recently various studies have shown its adverse effect on glucose control among diabetic patients and the U.S. Food and Drug Administration have revised statin drug labels to include information that increases in fasting serum glucose and glycated hemoglobin levels have been reported. This systematic review objective is to evaluate the risks and benefits of statins in glucose control management of type 2 diabetes patients based on the 44 published journal articles included and obtained through MEDLINE full text, PubMed, Science Direct, Pro Quest, SAGE, Taylor and Francis Online, Google Scholar, High Wire, and Elsevier Clinical Key. Statins were found to affect glucose control through several ways, namely, by affecting insulin production and secretion by β-pancreatic cells, insulin resistance, insulin uptake by the muscles and adipocytes and production of adipokines. Current evidence available shows that most of the statins give unfavorable side effects with regards to glucose control among diabetic patients. A dose-dependent and time-dependent effect was also observed in some statins which may be present among other statins as well.

Keywords

statins - glucose control - diabetes - hypercholesterolemia - insulin secretion - insulin sensitivity - insulin resistance
 

  • References

  • 1 Chinwong D, Patumanond J, Chinwong S. , et al. Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency. Ther Clin Risk Manag 2015; 11: 127-136
    PubMedGoogle Scholar
  • 2 Tziomalos K. Clinical controversies in lipid management. Panminerva Med 2015; 57 (02) 65-70
    PubMedGoogle Scholar
  • 3 Maddox TM, Borden WB, Tang F. , et al. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol 2014; 64 (21) 2183-2192
    CrossrefPubMedGoogle Scholar
  • 4 Kavousi M, Leening MJG, Nanchen D. , et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311 (14) 1416-1423
    CrossrefPubMedGoogle Scholar
  • 5 Wehrwein P. (Harvard Health Publications). Statin use is up, cholesterol levels are down: Are Americans' hearts benefiting? Available at: http://www.health.harvard.edu/blog/statin-use-is-up-cholesterol-levels-are-down-are-americans-hearts-benefiting-201104151518 . Accessed February 15, 2015
    PubMed
  • 6 Zhou Q, Liao JK. Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J 2010; 74 (05) 818-826
    CrossrefPubMedGoogle Scholar
  • 7 Šimić I, Reiner Ž. Adverse effects of statins - myths and reality. Curr Pharm Des 2015; 21 (09) 1220-1226
    CrossrefPubMedGoogle Scholar
  • 8 Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm . Accessed February 15, 2015
    PubMedGoogle Scholar
  • 9 Liew SM, Lee PY, Hanafi NS. , et al. Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes. Diabetol Metab Syndr 2014; 6: 53
    CrossrefPubMedGoogle Scholar
  • 10 Bellia A, Rizza S, Galli A. , et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis 2010; 210 (01) 199-201
    CrossrefPubMedGoogle Scholar
  • 11 Teramoto T, Urashima M, Shimano H, Yokote K, Saito Y. , LIVES Study Extension Group. A large-scale survey on cardio- cerebrovascular events during pitavastatin (LIVALO tablet) therapy in Japanese patients with hypercholesterolemia. Jpn Pharmacol Ther 2011; 39 (09) 789-803
    PubMedGoogle Scholar
  • 12 Mansi I, Frei CR, Wang CP, Mortensen EM. Statins and New-Onset Diabetes Mellitus and Diabetic Complications: A Retrospective Cohort Study of US Healthy Adults. J Gen Intern Med 2015; 30 (011) 1599-1610
    CrossrefPubMedGoogle Scholar
  • 13 Ahmed D, Sharma M, Pillai KK. The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats. Fundam Clin Pharmacol 2012; 26 (05) 621-631
    CrossrefPubMedGoogle Scholar
  • 14 Aguirre L, Hijona E, Macarulla MT. , et al. Several statins increase body and liver fat accumulation in a model of metabolic syndrome. J Physiol Pharmacol 2013; 64 (03) 281-288
    PubMedGoogle Scholar
  • 15 Otani M, Yamamoto M, Harada M, Otsuki M. Effect of long- and short-term treatments with pravastatin on diabetes mellitus and pancreatic fibrosis in the Otsuka-Long-Evans-Tokushima fatty rat. Br J Pharmacol 2010; 159 (02) 462-473
    CrossrefPubMedGoogle Scholar
  • 16 Liu PY, Lin LY, Lin HJ. , et al. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study). PLoS ONE 2013; 8 (10) e76298
    CrossrefPubMedGoogle Scholar
  • 17 Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58 (04) 773-795
    CrossrefPubMedGoogle Scholar
  • 18 PB PERKENI Indonesia. Konsensus Pengelolaan dan Pencegahan Diabetes Melilitus Tipe 2 di Indonesia 2011. Indonesia: Perkumpulan Endokrinologi; 2011
    Google Scholar
  • 19 American Diabetes Association. Standards of medical care in diabetes 2015: Clinical guideline. Diabetes Care 2015; 38 (Suppl. 01) S1-S94
    PubMedGoogle Scholar
  • 20 O'Keefe JH, DiNicolantonio JJ, Lavie CJ, Bell DS. The influence of statins on glucose tolerance and incipient diabetes. US Endocrinology 2014; 10 (01) 68-74
    CrossrefPubMedGoogle Scholar
  • 21 Sattar N, Taskinen MR. Statins are diabetogenic—myth or reality?. Atheroscler Suppl 2012; 13 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 22 Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007; 40 (9–10): 575-584
    CrossrefPubMedGoogle Scholar
  • 23 Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006; 13 (03) 123-129
    CrossrefPubMedGoogle Scholar
  • 24 Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis?. Curr Vasc Pharmacol 2010; 8 (05) 612-631
    CrossrefPubMedGoogle Scholar
  • 25 Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014; 63 (06) 735-745
    CrossrefPubMedGoogle Scholar
  • 26 Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE. Impact of simvastatin on adipose tissue: pleiotropic effects in vivo. Endocrinology 2009; 150 (12) 5262-5272
    CrossrefPubMedGoogle Scholar
  • 27 Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne) 2013; 4 (June): 71
    PubMedGoogle Scholar
  • 28 Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008; 34 (01) 2-11
    CrossrefPubMedGoogle Scholar
  • 29 Wanders D, Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World J Diabetes 2010; 1 (04) 116-128
    CrossrefPubMedGoogle Scholar
  • 30 Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010; 44 (01) 25-36
    CrossrefPubMedGoogle Scholar
  • 31 Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15 (18) 1851-1862
    CrossrefPubMedGoogle Scholar
  • 32 Benoit SC, Clegg DJ, Seeley RJ, Woods SC. Insulin and leptin as adiposity signals. Recent Prog Horm Res 2004; 59: 267-285
    CrossrefPubMedGoogle Scholar
  • 33 Abe M, Matsuda M, Kobayashi H. , et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-beta pathway in macrophages. Arterioscler Thromb Vasc Biol 2008; 28 (05) 871-877
    CrossrefPubMedGoogle Scholar
  • 34 Moutzori E, Liberopoulos E, Mikhailidis DP. , et al. Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract 2011; 65 (11) 1141-1148
    CrossrefPubMedGoogle Scholar
  • 35 Mitchell P, Marette A. Statin-induced insulin resistance through inflammasome activation: sailing between Scylla and Charybdis. Diabetes 2014; 63 (11) 3569-3571
    CrossrefPubMedGoogle Scholar
  • 36 Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010; 42 (04) 469-479
    CrossrefPubMedGoogle Scholar
  • 37 Smith R, Solberg R, Jacobsen LL. , et al. Simvastatin inhibits glucose metabolism and legumain activity in human myotubes. PLoS ONE 2014; 9 (01) e85721
    CrossrefPubMedGoogle Scholar
  • 38 Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev 2012; 40 (04) 188-194
    PubMedGoogle Scholar
  • 39 Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther 2010; 90 (10) 1530-1542
    CrossrefPubMedGoogle Scholar
  • 40 Suzuki M, Kakuta H, Takahashi A. , et al. Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice. J Atheroscler Thromb 2005; 12 (02) 77-84
    CrossrefPubMedGoogle Scholar
  • 41 Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003; 26 (12) 1681-1684
    CrossrefPubMedGoogle Scholar
  • 42 Newman CB, Szarek M, Colhoun HM. , et al; Cards Investigators. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diab Vasc Dis Res 2008; 5 (03) 177-183
    CrossrefPubMedGoogle Scholar
  • 43 Yokote K, Saito Y. ; CHIBA Study Investigators. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb 2009; 16 (03) 297-298
    CrossrefPubMedGoogle Scholar
  • 44 Mita T, Nakayama S, Abe H. , et al. Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia. J Diabetes Investig 2013; 4 (03) 297-303
    CrossrefPubMedGoogle Scholar
  • 45 Szotowska M, Czerwienska B, Adamczak M, Chudek J, Wiecek A. Effect of low-dose atorvastatin on plasma concentrations of adipokines in patients with metabolic syndrome. Kidney Blood Press Res 2012; 35 (04) 226-232
    CrossrefPubMedGoogle Scholar
  • 46 Huptas S, Geiss HC, Otto C, Parhofer KG. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006; 98 (01) 66-69
    CrossrefPubMedGoogle Scholar
  • 47 Endo K, Miyashita Y, Saiki A. , et al. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb 2004; 11 (06) 341-347
    CrossrefPubMedGoogle Scholar
  • 48 Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA. ; Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia 2009; 52 (01) 50-59
    CrossrefPubMedGoogle Scholar
  • 49 Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25 (07) 1198-1202
    CrossrefPubMedGoogle Scholar
  • 50 Kryzhanovski V, Gumprecht J, Zhu B, Yu CY, Hounslow N, Sponseller CA. Atorvastatin but not pitavastatin significantly increase plasma glucose in patients with type 2 diabetes and combined dyslipedemia. J Am Coll Cardiol 2011; 57 (14) 1113-1279
    CrossrefPubMedGoogle Scholar
  • 51 Ogawa H, Matsui K, Saito Y. , et al. Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study –. Circ J 2014; 78 (10) 2512-2515
    CrossrefPubMedGoogle Scholar
  • 52 Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49 (08) 1881-1892
    CrossrefPubMedGoogle Scholar
  • 53 Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008; 15 (05) 269-275
    CrossrefPubMedGoogle Scholar
  • 54 Takano T, Yamakawa T, Takahashi M, Kimura M, Okamura A. Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13 (02) 95-100
    CrossrefPubMedGoogle Scholar
  • 55 Her AY, Kim JY, Kang SM. , et al. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. J Cardiovasc Pharmacol Ther 2010; 15 (02) 167-174
    CrossrefPubMedGoogle Scholar
  • 56 Sasaki J, Ikeda Y, Kuribayashi T. , et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008; 30 (06) 1089-1101
    CrossrefPubMedGoogle Scholar
  • 57 Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010; 55 (12) 1209-1216
    CrossrefPubMedGoogle Scholar
  • 58 Simsek S, Schalkwijk CG, Wolffenbuttel BH. Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study. Diabet Med 2012; 29 (05) 628-631
    CrossrefPubMedGoogle Scholar
  • 59 Stalenhoef AFH, Ballantyne CM, Sarti C. , et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005; 26 (24) 2664-2672
    CrossrefPubMedGoogle Scholar
  • 60 Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes Obes Metab 2011; 13 (11) 1047-1055
    CrossrefPubMedGoogle Scholar
  • 61 Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004; 26 (10) 1599-1607
    CrossrefPubMedGoogle Scholar
  • 62 Daido H, Horikawa Y, Takeda J. The effects of pitavastatin on glucose metabolism in patients with type 2 diabetes with hypercholesterolemia. Diabetes Res Clin Pract 2014; 106 (03) 531-537
    CrossrefPubMedGoogle Scholar
  • 63 Kawai T, Tokui M, Funae O. , et al. Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care 2005; 28 (12) 2980-2981
    PubMedGoogle Scholar
  • 64 Yu Y, Ohmori K, Chen Y. , et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004; 44 (04) 904-913
    CrossrefPubMedGoogle Scholar
  • 65 Koh KK, Quon MJ, Sakuma I. , et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int J Cardiol 2013; 166 (02) 509-515
    CrossrefPubMedGoogle Scholar
  • 66 Mita T, Watada H, Nakayama S. , et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J 2007; 54 (03) 441-447
    CrossrefPubMedGoogle Scholar
  • 67 Miller AW, Tulbert CD, Busija DW. Rosuvastatin treatment reverses impaired coronary artery vasodilation in fructose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol 2004; 287 (01) R157-R160
    CrossrefPubMedGoogle Scholar
  • 68 Bellia A, Rizza S, Lombardo MF. , et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis 2012; 223 (01) 197-203
    CrossrefPubMedGoogle Scholar
  • 69 Wang L, Duan G, Lu Y. , et al. The effect of simvastatin on glucose homeostasis in streptozotocin induced type 2 diabetic rats. J Diabetes Res 2013; 2013: 274986
    PubMedGoogle Scholar
  • 70 Collins R, Armitage J, Parish S, Sleigh P, Peto R. ; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361 (9374): 2005-2016
    CrossrefPubMedGoogle Scholar
  • 71 Krysiak R, Okopien B. Different effects of simvastatin on ex vivo monocyte cytokine release in patients with hypercholesterolemia and impaired glucose tolerance. J Physiol Pharmacol 2010; 61 (06) 725-732
    PubMedGoogle Scholar
  • 72 Szendroedi J, Anderwald C, Krssak M. , et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care 2009; 32 (02) 209-214
    CrossrefPubMedGoogle Scholar
  • 73 Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism 2010; 59 (06) 921-926
    CrossrefPubMedGoogle Scholar
  • 74 Sukhija R, Prayaga S, Marashdeh M. , et al. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med 2009; 57 (03) 495-499
    CrossrefPubMedGoogle Scholar
  • 75 Pollak AW, Kramer CM. LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?. Clin Lipidol 2012; 7 (02) 141-149
    CrossrefPubMedGoogle Scholar